Prenetics Raises FY 2026 Guidance Following 288% Surge in IM8 Revenue

Key Facts

1Prenetics' IM8 unit reported Q2 2026 revenue growth of 288% year-over-year.

2The company raised its FY 2026 IM8 revenue guidance to a range of $220–230 million.

3Consolidated adjusted free cash flow turned positive in July and is expected to remain so for Q3 and beyond.

In a move reflecting rapid expansion within the consumer health sector, Prenetics reported strong Q2 2026 results driven by the exceptional performance of its IM8 unit. The IM8 business recorded a 288% year-over-year revenue surge, prompting the company to raise its full-year 2026 revenue guidance to a range of $220 million to $230 million. Additionally, the group reached a significant financial milestone as consolidated adjusted free cash flow turned positive for the first time in July.

This robust growth stems from the scaling of the IM8 brand, which reached an annualized revenue run-rate of approximately $251 million within just 20 months of launch. According to reports, strategic partnerships and a global footprint spanning 46 countries have fueled this momentum, with the unit now delivering over 200,000 daily servings. Management expects the positive cash flow trajectory to persist through the third quarter and beyond, strengthening the company's financial position during its current growth phase.

Operationally, markets are monitoring the company's ability to maintain this upward trajectory, with 2027 IM8 revenue targets set at $400 million or more. Regarding broader economic context, investors are looking at US Existing Home Sales (reported at 4.06 million on August 11, 2026) and global inflation data to gauge retail sector risk appetite, noting that updated price levels for the instrument were unavailable at the time of this report.

Sources:

globenewswire.com